Key Points
This is the first vaccine against Tuberculosis derived from a human source by the Spanish biopharmaceutical company, Biofabri, a press release from Bharat Biotech said...
The release said that Mtbvac is being developed for two purposes; firstly, as a more effective and potentially longer-lasting vaccine than BCG ( Bacillus Calmette Guerin) for newborns and secondly, for the prevention of TB in adults and adolescents, for whom there is currently no effective vaccine...
Krishna Ella, Executive Chairman Bharat Biotech said "Our quest for a more effective vaccine against Tuberculosis received a big boost today, with clinical trials in India..
After the recent completion of a Phase-2 dose finding trial, a double-blind controlled Phase-3 clinical trial in newborns has been started in 2023 to compare the vaccine with the current BCG vaccine...
You might be interested in
Bharat Biotech starts clinical trials of TB jab
25, Mar, 24The only vaccine in use today--BCG (Bacillus Calmette and Guerin)--is an attenuated variant of the bovine TB pathogen. This is more than a hundred years old and has a limited effect on pulmonary tuberculosis, which is mostly responsible for the transmission of the disease. Studying the safety, immunogenicity and efficacy of MTBVAC in the most populated country in the world and the one with the highest number of cases of this infectious disease is key to continue advancing in this vaccine, the company said.
Bharat Biotech begins clinical trials of more effective TB vaccine in India
25, Mar, 24India News: HYDERABAD: Bharat Biotech, based in Hyderabad, has started clinical trials of MTBVAC, the world's first Mycobacterium tuberculosis vaccine derived fro.